We recently had the opportunity to interview Professor Patrick Pauwels, head of the laboratory of molecular pathology and co-director of CORE (Center for Oncological Research), a joint oncology research platform with the University of Antwerp.
Professor Pauwels has a principle interest in biomarker research in oncology, with a particular focus on liquid biopsies.
You can listen to the full interview through our podcast:
Here are some of the key highlights from our discussion:
Early detection of cancer can greatly increase chances of survival and improve overall quality of life. Traditionally, a tissue biopsy is the common approach to diagnose many cancers. However, obtaining a tissue sample is difficult and not always possible. In this podcast, we discuss the potential of liquid biopsies, in particular urine as a sample type in the field of cancer research, especially when tissue is an issue. The podcast also highlights URODETECT, a collaborative project between CORE and Novosanis, which focuses on investigating urinary biomarkers for prostate and breast cancer using the Colli-Pee® device. Colli-Pee® allows volumetric and standardized collection of first-void urine.
Tune in to hear Professor Pauwels’ view on some of the following questions:
Why is biomarker research playing an important role in clinical cancer research?
Why are you particularly interested in liquid biopsies?
From your experience in the clinic, how do patients react if they can be helped by means of a liquid biopsy rather than the standard alternatives?
What are the different types of liquid biopsies?
Are all liquid biopsy types equal? Do you see an advantage of using urine?
What are the goals of URODETECT? What do you expect from this project?
What will be the impact of URODETECT on cancer research and treatment?